Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Testolactone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 15/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Testolactone SCHEMBL2300061 | 1.00 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Testolactone SCHEMBL5083091 | 0.94 | CYP19A1 (0.89) | CYP19A1LMNAMAPTCYP3A4 | |
| Testolactone SCHEMBL28867264 | 0.92 | CYP19A1 (0.84) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL8980363 | 0.84 | CYP19A1 (0.72) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL23691780 | 0.80 | CYP19A1 (0.67) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL8393653 | 0.80 | CYP19A1 (0.67) | CYP19A1LMNAMAPTCYP3A4 | |
| Testolactone SCHEMBL13732511 | 0.80 | CYP19A1 (0.64) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL14450072 | 0.80 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL134061 | 0.80 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Androstenedone SCHEMBL12430773 | 0.80 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 59874 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4735116-A2 | ANTI-TRAILR2 ANTIGEN-BINDING PROTEINS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-3645742-B1 | ANTI-ROR1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260108476-A1 | 2,4 DNP and Prodrugs Thereof for Treatment of Cancer | MITOCHON PHARMACEUTICALS, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0479867-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES. | COHEN MICHAEL (NL) | 1992-04-15 | — | — | EP | claimed |
| WO-1991000095-A1 | COMPOSITIONS USEFUL AS CONTRACEPTIVES IN MALES | COHEN MICHAEL (NL) | 1991-01-10 | — | — | WO | claimed |
| CN-1048327-A | Contraceptive composition for male | COHEN MICHAEL (NL) | 1991-01-09 | — | — | CN | claimed |
| US-4598072-A | Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperplasia | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | claimed |
| US-4596797-A | Urogenital disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-06-24 | — | — | US | claimed |
| EP-0179062-A1 | PROPHYLAXIS AND THERAPY OF CORONARY HEART DISEASES BY LOWERING THE ESTROGEN CONCENTRATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-04-30 | — | — | EP | claimed |
| WO-1985000107-A1 | PROPHYLAXIS AND THERAPY OF CORONARY HEART DISEASES BY LOWERING THE ESTROGEN CONCENTRATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-01-17 | — | — | WO | claimed |